Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

Authors: Fukuoka K.1; Usuda J.2; Iwamoto Y.2; Fukumoto H.2; Nakamura T.2; Yoneda T.3; Narita N.3; Saijo N.2; Nishio K.2

Source: Investigational New Drugs, Volume 19, Number 3, August 2001 , pp. 219-227(9)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

E7070 is a novel sulfonamide antitumor agent that exhibits potent antitumor activity in vitro and in vivo. This compound affects cell cycle progression in human tumor cells. To elucidate the mechanisms by which E7070 inhibits tumor cell growth, we established and characterized an E7070-resistant subline, A549/ER, from a human non-small cell lung cancer cell line A549. Flow cytometric analyses demonstrated an increase in G0/G1 and a decrease in S phase populations in cells treated with E7070 at 20 or 100 mug/ml for 24 h. Longer exposure to E7070, i.e. 48 and 72 h, increased the G2/M phase fraction in A549 cells. These inhibitory actions of E7070 on cell cycle progression were not observed in A549/ER cells. E7070 inhibited the phosphorylation of pRb, decreased expressions of cyclin A, B1, CDK2, and CDC2 proteins, and suppressed CDK2 catalytic activity with the induction of p53 and p21 proteins in A549 cells but not in A549/ER cells. Taken together, these results suggest that E7070 exerts its antitumor effects by disturbing the cell cycle at multiple points, including both the G1/S and the G2/M transition, in human lung cancer cells.

Keywords: sulfonamide; E7070; cell cycle; G1 arrest; lung cancer cells; resistant cells

Language: English

Document Type: Regular paper

Affiliations: 1: Pharmacology Division, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo; Second Department of Internal Medicine, Nara Medical University, Shijo-cho, Kashihara-city, Nara, Japan 2: Pharmacology Division, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo 3: Second Department of Internal Medicine, Nara Medical University, Shijo-cho, Kashihara-city, Nara, Japan

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A